Proteomic identification of aldolase A as an autoantibody target in patients with atypical movement disorders

• Published in: Neurological sciences Vol. 34; no. 3; pp. 313 - 320
• Main Authors: Privitera, Daniela, Corti, Valeria, Alessio, Massimo, Volontè, Antonietta, Lampasona, Vito, Comi, Giancarlo, Martino, Gianvito, Franciotta, Diego, Furlan, Roberto, Fazio, Raffaella
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 01.03.2013; Springer Nature B.V
• Subjects: Aged; Autoantibodies; Autoantibodies - metabolism; Autoantigens; Autoimmune diseases; Basal ganglia; biomarkers; Brain; Central nervous system; Central nervous system diseases; Electrophoresis, Gel, Two-Dimensional; Enzyme-Linked Immunosorbent Assay; Female; Fructose-Bisphosphate Aldolase - immunology; Fructose-Bisphosphate Aldolase - metabolism; Glycolysis; Humans; Male; Mass spectroscopy; Medicine; Medicine & Public Health; Movement disorders; Movement Disorders - classification; Neurodegenerative diseases; Neurological diseases; Neurology; Neuroradiology; Neurosciences; Neurosurgery; Original Article; Parkinson's disease; Probes; Proteomics; Psychiatry; Retrospective Studies; Rhythms; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Western blotting; Hyperkinetic movement disorders; SERPA; Aldolase A
• DOI: 10.1007/s10072-012-0996-y
• ISSN: 1590-1874

We tried to identify the target/s of autoantibodies to basal ganglia neurons found in a patient with hyperkinetic movement disorders (HMD) characterized by rapid, rhythmic involuntary movements or spasms in both face and neck. Patient and control sera were used in Western blot to probe mouse brain homogenates. Two-dimensional gel electrophoresis (2-DE) SDS-PAGE protein spots recognized by the patient’s antibodies were excised and sequenced by mass spectrometry analysis, and the glycolytic enzyme aldolase A was identified as the antigen recognized by the patient’s autoantibodies. To assess relevance and specificity of these antibodies to the identified targets as biomarkers of autoimmunity in movement disorders, autoantibody responses to the identified target were then measured by ELISA in various diseases of the central nervous system. Anti-aldolase A autoantibodies were associated mainly with HMD (7/17, 41%) and Parkinson’s disease (4/30, 13%) patients, and undetectable in subjects with other inflammatory and non-inflammatory central nervous system diseases. We, thus, identified aldolase A as an autoantigen in a sub-group of patients with HMD, a clinically ill-defined syndrome. Anti-aldolase A antibodies may represent a useful biomarker of autoimmunity in HMD patients.